Latest Partnerships News

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

American Rare Earths has partnered with Novex to tackle the critical oxide-to-metal bottleneck in the US rare earth supply chain, aiming to establish a fully domestic mine-to-magnet value chain from its Halleck Creek Project.

Viridis Mining and Minerals Limited (ASX: VMM) has halted trading of its shares pending the release of its Definitive Feasibility Study results, with the suspension expected to last until 20 August 2026 or earlier if the announcement is made sooner.

ABx Group secures environmental approvals consultancy for Sunrise Bauxite Project as Good Importing International invests A$2.7 million for a 70% stake. GII's option on NSW assets expires, leaving ABx with full control.

Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.

Forrestania Resources has awarded a significant A$27 million contract to MEGA Resources for the initial open pit mining phase at its Tycho Gold Project, marking a pivotal move from development to production.

Iress Limited’s half year net profit after tax surged 85% to $32 million, driven by sharp cost cuts and margin expansion, even as total revenue fell nearly 17% following recent divestments.

Locksley Resources has ceased active exploration at its US critical minerals projects following a technical review and a sharp drop in antimony prices, opting to maintain claims on a low-cost basis while reassessing its hydrometallurgical technology partnership.

The Calmer Co. has locked in an exclusive global distribution agreement for its kava extract ingredients, underpinning a potential A$25 million revenue stream over three years across key markets including the US and ASEAN.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

Doctor Care Anywhere delivered a 27% rise in EBITDA and doubled free cash flow in H1 2026, driven by operational efficiencies and a strategic entry into the UK weight management market via acquisition.

Growthpoint Properties Australia reported a statutory net profit of $90.1 million for FY26, underpinned by record leasing activity and achievement of its Net Zero Target. The group maintained strong portfolio occupancy at 96%, grew funds under management, and provided FY27 guidance reflecting ongoing macroeconomic caution.